Apo(a) phenotyping and long-term prognosis for coronary artery disease

Clinical Biochemistry

Volumn 43, Issue 7-8, 2010, Pages 640-644

  Banos Gonzalez M A ^a   Pena Duque M A ^a   Angles Cano E ^c   Martinez Rios, M A ^a   Bahena, A ^d   Valente Acosta, B ^b   Cardoso Saldana G ^a   Angulo Ortiz J ^a   de la Pena Diaz A ^a,b  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSERM   (France)

^d NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Apo(a) phenotyping; Cardiovascular disease; Long term prognosis; Lp(a); Stroke

Indexed keywords

APOLIPOPROTEIN A; FIBRIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; SURVIVAL RATE; UNSTABLE ANGINA PECTORIS;

ADULT; ANGINA, UNSTABLE; APOLIPOPROTEINS A; CORONARY ARTERY DISEASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FIBRIN; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PHENOTYPE; PROGNOSIS; PROTEIN BINDING; STROKE;

EID: 77951205211     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.01.013     Document Type: Article

References (42)

1. McLean J.W., Tomlinson J.E. Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 300:132-137.
2. Guevara J., Knapp R.D., Honda S., Northup S.R., Morrisett J.D. A structural assessment of the apo (a) protein of human lipoprotein (a). Proteins 1992, 12:188-199.
3. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., Seitz C. Lp (a) glycoprotein phenotypes: inheritance and relation to Lp (a)-lipoprotein concentrations in plasma. J. Clin. Invest. 1987, 80:458-465.
4. De la Peña-Díaz A., Izaguirre-Avila R., Anglés-Cano E. Lipoprotein Lp(a) and atherothrombotic disease. Arch. Med. Res. 2000, 31:353-359.
5. Lamanuzzi L.B., Mtairag el M., Pepe G., Anglés-Cano E. Neutrophils stimulated by apolipoprotein(a) generate fragments that are stronger inhibitors of plasmin formation than apo(a). Thromb. Haemost. 2004, 92:1066-1075.
6. Anglés-Cano E., de la Peña Díaz A. Loyau, Inhibition of fibrinolysis by lipoprotein(a). Ann. N.Y. Acad. Sci. 2001, 936:261-275.
7. Kang C., Dominguez M., Loyau S., Miyata T., Durlach V., Anglés-Cano E. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1232-1238.
8. Feric N.T., Boffa M.B., Johnston S.M., Koschinsky M.L. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. J. Thromb. Haemost. 2008, 6:2113-2120.
9. Undas A., Stepien E., Tracz W., Szczeklik A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J. Thromb. Haemost. 2006, 4:973-975.
10. Caplice N.M., Panetta C., Peterson T.E., et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitos: a novel link between lipoproteins and thrombosis. Blood 2001, 98:2980-2987.
11. Martínez C., Rivera J., Loyau S., et al. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb. Haemost. 2001 Apr, 85(4):686-693.
12. Cho T., Jung Y., Koschinsky M.L. Apolipoprotein(a), through its strong lysine-binding site in KIV(19'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J. Biol. Chem. 2008, 283:30503-30512.
13. Pellegrino M., Furmaniak-Kazmierczak E., Le Blanc J.C., et al. The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J. Biol. Chem. 2004, 279:6526-6533.
14. Devlin C.M., Lee S.J., Kuriakose G., et al. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1704-1710.
15. Nardulli M., Durlach V., Pepe G., Anglés-Cano E. Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma. Thromb. Haemost. 2005, 94:75-81.
16. Kiechl S., Willeit J., Mayr M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1788-1795.
17. Sotiriou S.N., Orlova V.V., Al-Fakhri N., et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J. 2006, 20:559-561.
18. Edelstein C., Philips B., Pfaffinger D., Scanu A.M. The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin. FASEB J. 2009, 23:950-956.
19. Liu L., Craig A.W., Meldrum H.D., Marcovina S.M., Elliott B.E., Koschinsky M.L. Apolipoprotein (a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3. Biochem. J. 2009, 418:325-336.
20. Cho T., Jung Y., Koschinsky M.L. Apolipoprotein(a), through its strong lysine-binding site in KIV(19'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J. Biol. Chem. 2008, 283:30503-30512.
21. Craig W.Y., Neveux L.M., Palomaki G.E., Cleveland M.M., Haddow J.E. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin. Chem. 1998, 44:2301-2306.
22. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102:1082-1085.
23. Haffner S.M., Gruber K.K., Morales P.A., et al. Lipoprotein(a) concentrations in Mexican Americans and non-Hispanic whites: the San Antonio Heart Study. Am. J. Epidemiol. 1992, 136:1060-1068.
24. Cardoso-Saldaña G., De la Peña-Díaz A., Zamora-González J., et al. Ethnicity and lipoprotein(a) polymorphism in Native Mexican populations. Ann. Hum. Biol. 2006, 33:202-212.
25. De la Peña-Díaz A., Cardoso Saldaña G., Zamora-González J., et al. Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases. Eur. J. Clin. Invest. 2003, 33:99-105.
26. Anglés-Cano E., Loyau S., Cardoso-Saldaña G., Couderc R., Gillery P. A novel kringle-4 number-based recombinant apo[a] standard for human apo[a] phenotyping. J. Lipid Res. 1999, 40:354-359.
27. Soulat T., Loyau S., Baudouin V., et al. Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: an in vitro study using plasma from children with idiopathic nephrotic syndrome. Arterioscler. Thromb. Vasc. Biol. 2000, 20:575-584.
28. Hervio L., Durlach V., Girard-Globa A., Anglés-Cano E. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry 1995, 34:13353-13358.
29. Longenecker J.C., Klag M.J., Marcovina S.M., et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J. Am. Soc. Nephrol. 2005, 16:1794-1802.
30. Kronenberg F., Kronenberg M.F., Kiechl S., et al. Role of lipoprotein (a) and apolipoprotein (a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999, 100:1154-1160.
31. Marcucci R., Brogi D., Sofi F., et al. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart 2006, 92:377-381.
32. Marcovina S.M., Kochinsky M.L., Albers J.J., Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clin. Chem. 2003, 49:1785-1796.
33. Marcovina S.M., Gaur V.P., Albers J.J. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein (a), and apolipoproteins A-I and B. Clin. Chem. 1994, 40:574-578.
34. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331-2339.
35. Clarke R., Peden J.F., Hopewell J.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 2009 Dec 24, 361(26):2518-2528.
36. Ariyo A., Thach C., Tracy R. Cardiovascular Health Study Investigators. Lp(a) Lipoprotein, Vascular Disease, and Mortality in the Elderly. N. Engl. J. Med. 2003, 349:2108-2115.
37. Tsimikas S., Clopton P., Brilakis E.S., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 2009, 119:1711-1719.
38. Armstrong V.W., Cremer P., Eberle E., et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis 1986, 62:249-257.
39. Nardulli M., Durlach V., Pepe G., Anglés-Cano E. Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma. Thromb. Haemost. 2005, 94:75-81.
40. Huby T., Afzal V., Doucet C., et al. Regulation of the expression of the apolipoprotein(a) gene: evidence for a regulatory role of the 5' distal apolipoprotein(a) transcription control region enhancer in yeast artificial chromosome transgenic mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1633-1639.
41. Akaike M., Azuma H., Kagawa A., et al. Effect of aspirin treatment on serum concentrations of lipoprotein (a) in patients with atherosclerotic diseases. Clin. Chem. 2002, 48:1454-1459.
42. Merki E., Gram M.J., Mulick A.E., et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008, 118:743-753.